Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
WINT(WINT) The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders
Windtree Therapeutics Stock Is Volatile This Week: What's Going On?
WINTWindtree Therapeutics Inc (NASDAQ:WINT) shares have trended lower over the past two trading sessions following a strong surge in shares on Tuesday. Here's a look at what's going on.
Windtree Therapeutics Stock Is Volatile This Week: What's Going On?
WINTWindtree Therapeutics Inc (NASDAQ:WINT) shares have trended lower over the past two trading sessions following a strong surge in shares on Tuesday. Here's a look at what's going on.
Windtree Receives Non-Binding Letter Of Intent To Purchase Its Preclinical Oncology Drug Candidate For $7M Up Front And Up To $130M In Milestones With Up To $1.5B In Royalties
WINTWindtree Stock Is Rising Tuesday: What's Going On?
WINTWindtree announced it will acquire Titan Environmental Services.
Windtree To Acquire Titan Environmental Services; Says Refocused Strategy Expected To Generate $12M In Revenue Over Next 12 Months
WINTWindtree Therapeutics to Establish Cryptocurrency Policy Enabling Crypto Payments And Long-Term Holdings As Strategic Assets
WINTWindtree Therapeutics Plans Interim Analysis Results For Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study For July 2025
WINTWindtree Therapeutics Q4 EPS $(4.63) Beats $(28.82) Estimate
WINTWindtree Therapeutics Received Advice From Intellectual Property And FDA Experts; Istaroxime May Receive New Chemical Entity Designation; Istaroxime Has USPTO Issued Method Of Patent Providing Protection Until 2039 And Pedning Method Of Using Patent Provi
WINTWindtree Therapeutics Secures Rights To Acquire 436-Unit Multifamily Property In Houston
WINTWindtree Therapeutics FY 2024 GAAP EPS $(104.35)
WINTWhat's Going On With Windtree Therapeutics (WINT) Stock?
WINTWindtree Therapeutics shares are trading higher by 37% during Monday's session. The company regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing.
Windtree Therapeutics Regains Nasdaq Listing Rule Compliance
WINTWhat's Going On With Windtree Therapeutics Shares Thursday?
WINTWindtree shares are trading higher on Thursday after the company entered a license and supply agreement with Evofem.
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On?
WINTWindtree Therapeutics shares are trading lower by 20% during Tuesday's session. The company announced the USPTO issued a Notice of Allowance for a patent.
Windtree Announces USPTO Issued Notice Of Allowance Of US Patent Titled 'ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE'
WINTWindtree Announces The Company Has Filed A National Phase Patent Application With The Indian Patent Office Claiming Priority To PCT/US2024/058923 Entitled, ISTAROXIME AND DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHM
WINTTrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
WINTTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
WINTWindtree Therapeutics, Inc. Announces 1-for-50 Reverse Stock Split, Effective On Feb. 20
WINTWindtree Therapeutics Announces That An Istaroxime Presentation Featuring The Phase 2B Seismic Study Was Given On February 11, 2025 At The Technology And Heart Failure Therapeutics Conference In Boston, Massachusetts
WINTWindtree Announces Japanese Patent Titled Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers. Expiring In 2040
WINTWindtree Announces Craig Fraser Plans To Retire From His Role As Chief Executive Officer, Effective December 1, 2024, Will Remain On The Board Of Directors Of The Company As Chairman; Board Has Appointed Jed Latkin, A Current Director Of The Company, To R
WINTWindtree Announces Expansion Of Patents With Issuance Of Istaroxime Patent For The Treatment Of Heart Failure, For Hong Kong
WINT